Anti-Human IL 12/23 (Briakinumab) APC
For estimated delivery dates, please contact us at firstname.lastname@example.org
|Amount :||50 µg|
|Isotype :||Human IgG1lambda|
|Content :||Concentration : 0.2 mg/ml
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
|Storage condition :||This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.|
|Alternative Name :||IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23|
|Immunogen Information :||This antibody was produced by phage display technology.|
Expression Host : HEK-293
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews